March 13, 2018
A triple drug combination can significantly reduce blood pressure (BP) among individuals with hypertension compared with usual care, according to results of a new study.
Results were presented at the American College of Cardiology 18 Scientific Sessions this morning.
To examine whether initial treatment with a low-dose triple therapy would safely achieve BP targets, the researchers conducted the Triple Pill vs Usual Care Management for Patients With Mild-Moderate Hypertension study in Sri Lanka.
Overall, 700 adults with hypertension that required initiation or up-titration of medication were included in the study.
Participants were randomly assigned to a fixed-dose combination of telmisartan, 20mg, amlodipine, 2.5mg, and chlorthalidone, 12.5mg (Triple Pill group), or a usual care group.
The researchers defined the primary outcome as a BP at or below 140/90 mmHg, or at or below 130/80 mmHg in patients with diabetes or chronic kidney disease.
At 6 months, 83% of participants in the Triple Pill group were still receiving all 3 study drugs.
The Triple Pill regimen had helped participants achieve the primary outcome at 6 months compared with usual care (70% vs 55%). The greatest difference was seen at 6 weeks of treatment (68% vs 44%).
In addition, adverse events were similar between the groups (38.7% vs 34.7%).
“Initial use of low-dose triple combination therapy is a safe and highly effective strategy to rapidly achieve BP control,” the researchers concluded.
For more Pharmacy Learning Network articles, visit the homepage
To learn about Pharmacy Learning Network Live meetings, click here